Rasagiline-¹³C₃ mesylate  (Synonyms: (R)-AGN1135-¹³C₃ mesylate; TVP1012-¹³C₃ mesylate)

Rasagiline-¹³C₃ ((R)-AGN1135-¹³C₃; TVP1012-¹³C₃) mesylateis the deuterium labeledRasagiline (mesylate)(HY-14605)^[1]. Rasagiline (R-AGN1135) mesylate is a highly potent selective irreversible mitochondrial monoamine oxidase (MAO) inhibitor with IC₅₀s of 4.43?nM and 412?nM for rat brain MAO B and A activity, respectively^[2].

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

270.32

C₁₀¹³C₃H₁₇NO₃S

1391052-18-8

161735-79-1

CS(=O)(O)=O.[13CH]#[13C][13CH2]N[C@H]1C2=CC=CC=C2CC1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.  [Content Brief]